XBIT XBiotech Inc.: Bozor kapitallashuvining balans qiymatiga nisbati

xbiotech.com (XBIT) - korporativ logo

XBiotech Inc. (XBIT) kompaniyasining narxlar dinamikasida aks etgan bozor holati 0.44 ning joriy ko'rsatkichi ekanligini namoyish etmoqda. Yuqori sinov xarajatlari kompaniyani investitsiyalarning turg'unlik bosqichida ushlab turibdi. Biznes nojo'ya reaksiyalar xavfi minimal bo'lgan o'simtaga qarshi dori vositalarini sintez qilish uchun True Human texnologiyasiga tayanadi. Biroq, keng mahsulotlar qatorining yo'qligi va patent muddatining tugashi bilan bog'liq xatarlar aksiyadorlar kapitalining uzoq muddatli barqarorligiga ma'lum tahdidlar tug'diradi.

XBiotech (XBIT) - Bozor kapitallashuvining balans qiymatiga nisbati 04.07.2022dan 27.10.2026gacha

XBIT (XBiotech Inc.): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari xbiotech.com|XBIT - Tahlilchilarning prognoz narxlari
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi XBiotech USA|XBIT - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati XBiotech|XBIT - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati xbiotech.com|XBIT - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati XBiotech Inc.|XBIT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati xbiotech.com|XBIT - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati XBiotech USA
Fundamental baholash:XBIT (XBiotech Inc)
XBiotech Inc. tayyor mahsulotlari

Investorlar XBiotech Inc. (XBIT) moliyaviy hisobotlaridan ichki qiymatning ob'ektiv belgilarini qidirmoqdalar. Ushbu ko'rsatkich aksiyalarning bozor narxini sof aktivlar bilan solishtirib, biznesning qanchalik hadda qimmat baholangani yoki arzon baholanganini ochib beradi. Bozor kapitalizatsiyasining kitob qiymatiga nisbatini tahlil qilish fundamental chegirmaning dinamikasini kuzatish imkonini beradi. No-tsiklik antitanalar ishlab chiqish sohasi uchun ushbu metrika sezilarli naqd pul zaxiralari hisobiga barqarorlikni tasdiqlaydi. Barqaror likvidlik yostig'i uzoq muddatli tadqiqotlarni rejalashtirish davrida xatarlarni minimallashtiradi.

Asosiy raqobatchilar

ONC - Kapitallashuvning sof aktivlarga nisbati|halozyme.com (HALO) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti CEL-SCI Corp (CVM)|Kapitallashuvning sof aktivlarga nisbati OS Therapies Incorporated OSTX|Kapitallashuvning balans qiymatiga nisbati Radiopharm Theranostics Ltd (RADX)|Bozor kapitallashuvining balans qiymatiga nisbati Artiva Biotherapeutics ARTV|Bozor qiymatining balans qiymatiga nisbati Adlai Nortye Ltd ANL|Bozor kapitallashuvining balans qiymatiga nisbati VERU (Veru Pharma)|TPST: Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati XLO|Bozor qiymatining balans qiymatiga koeffitsiyenti Renovaro|Mural Oncology PLC (MURA) - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga multiplikatori Kairos Pharma Inc|OnKure Therapeutics Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti w2.cytomed.sg (GDTC)|Curis - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Apollomics Inc. APLM|Bozor kapitallashuvining balans qiymatiga nisbati Tharimmune (THAR)|Advanced Biomed Inc (ADVB) - Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati Genprex, Inc GNPX|Calidi Biotherapeutics, Inc. (CLDI) - Balans qiymatiga nisbatan bozor qiymati|SBFM: Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi XBIO|Bozor qiymatining balans qiymatiga nisbati Salarius Pharmaceuticals, Inc. SLRX|Kapitallashuvning balans qiymatiga nisbati Purple Biotech Ltd (PPBT)|American Oncology Network, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|BGNE - Kapitallashuvning sof aktivlarga nisbati|Kapitallashuvning sof aktivlarga nisbati CKPT (Checkpoint Therapeutics)|Elevation Oncology Inc. (ELEV) - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati icadmed.com|Ikena Oncology (IKNA) - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati Notable Labs Inc.|Bozor qiymatining balans qiymatiga nisbati Viracta|MOR (MorphoSys AG) - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi nayabiosciences.com NAYA|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma (AAPGV)